Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC2R | Q01718 | 12/20 | 0.55 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30138108 | 0.97 | MC2R (0.57) | MC2RHTR1BPPARGENPP2 | |
| SCHEMBL30649058 | 0.91 | MC2R (0.54) | MC2RHTR1BPPARGENPP2 | |
| SCHEMBL26641018 | 0.91 | MC2R (0.54) | MC2RHTR1BPPARGENPP2 | |
| SCHEMBL21700582 | 0.91 | MC2R (0.61) | MC2RHTR1BACP1 | |
| SCHEMBL23201627 | 0.90 | MC2R (0.61) | MC2RHTR1BPPARGENPP2 | |
| SCHEMBL21700622 | 0.90 | MC2R (0.61) | MC2RHTR1BPPARGENPP2 | |
| SCHEMBL30138137 | 0.88 | MC2R (0.61) | MC2RHTR1B | |
| Trifluoroacetic Acid SCHEMBL21700766 | 0.87 | MC2R (0.63) | MC2RHTR1BACP1 | |
| SCHEMBL21700754 | 0.86 | MC2R (0.68) | MC2RHTR1BACP1 | |
| Trifluoroacetic Acid SCHEMBL21700757 | 0.84 | MC2R (0.69) | MC2RHTR1BACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802500-B1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12479828-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20240300920-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2024-09-12 | — | — | US | disclosed |
| US-20240109866-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2024-04-04 | — | — | US | disclosed |
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | MC2R 3/4885HTR1B 67/4885PPARG 361/4885 |
| US-20240109866-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | MC2R 3/4885HTR1B 67/4885PPARG 361/4885 |
| US-20240300920-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | MC2R 3/4885HTR1B 67/4885PPARG 361/4885 |
| US-12479828-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | MC2R 3/4885HTR1B 67/4885PPARG 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.